Search Results
Results found for "Inversago Pharma"
- Delineation of GPR15 receptor-mediated Gα protein signaling profile in recombinant mammalian cell
Here, GPR15L(25-81) and GPR15L(71-81) are used as pharmacological tool compounds to delineate the GPR15
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
inactive conformation using molecular dynamic simulations "The δ-opioid receptor (DOR) is a critical pharmaceutical
- Isoforms of GPR35 have distinct extracellular N-termini that allosterically modify...
The pharmacological profiles and mechanistic insights of our study provide clues for the future design
- A broad look into the future of systemic sclerosis
Pharmacological interventions, although for other indications, are already in clinical use to address
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
receptors (SSTs) are class A GPCRs abundantly expressed in pituitary tumors where they represent the main pharmacological
- Interacting binding insights and conformational consequences of the differential activity of...
major non-psychoactive phytocannabinoid present in the plant Cannabis sativa, has displayed beneficial pharmacological Our work will pave the way for understanding the CBD pharmacology at a molecular level and aid in harnessing
- GPCR kinase phosphorylation of distal C-tail sites specifies βarrestin1-mediated signaling by...
We demonstrate by pharmacologic inhibition of GRK2/3-mediated phosphorylation of the chemokine receptor
- Addex Raises $10 Million In Equity Financing
Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Ermium Therapeutics has constituted its SAB
Therapeutics Announces the Formation of a Scientific Advisory Board comprising international leaders in GPCRs pharmacology
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
of GPR84 and, in the absence of direct structural information, recent developments and use of GPR84 pharmacological
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
"Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
evaluate parathyroid hormone (PTH) and PTH-related protein (PTHrP) ligands and analogues for their pharmacologic
- Addex raises $4.2 million in equity financing
Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Michel Bouvier appointed Knight of the Ordre national du Québec
22, 2022, Michel Bouvier, Chief Executive Officer of IRIC, Principal Investigator of the Molecular Pharmacology
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
He received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of Pharmacy and Science.
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
chaperones to improve the folding and stability of the mutant receptor is one of the most promising pharmacological
- Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes
in nearly all physiological systems make GPCR the largest protein family targeted for development of pharmaceuticals
- Targeted Activation of G-Protein Coupled Receptor-Mediated Ca 2+ Signaling Drives Enhanced Cartilage
Control of chondrocyte/chondroprogenitor Ca2+ signaling has been attempted through mechanical and/or pharmacological
- Dr. Nicola J. Smith - Dr. GPCR Podcast
Nicola Smith, Molecular Pharmacologist, lab head, and senior lecturer at UNSW Sydney.
- Applications of Cryo-EM in small molecule and biologics drug design
In recent years, pharmaceutical companies have begun to utilize cryo-EM for structure-based drug design
- Obesity-induced changes in human islet G protein-coupled receptor expression: Implications for ...
GPCRs) are a large family of cell surface receptors that are the targets for many different classes of pharmacotherapy
- Phenylalanine 193 in Extracellular Loop 2 of the β 2-Adrenergic Receptor Coordinates β-Arrestin ...
that can provide insight into this aspect of GPCR signaling thanks to robust structural data and rich pharmacopeia
- TLR4 biased small molecule modulators
Biased pharmacological modulators provide potential therapeutic benefits, including greater pharmacodynamic
- Coordinated transcriptomics and peptidomics of central nervous system identify neuropeptides and ...
together, these results will benefit further investigations to determine physiological functions and pharmacological
